← Back to Search

Antifibrinolytic Agent

Tranexamic Acid Arm (TXA) for Hip Fracture

Phase 2
Waitlist Available
Led By Brandon Yuan, MD
Research Sponsored by Mayo Clinic
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up length of hospitalization (approximately 3 to 5 days)
Awards & highlights

Study Summary

This trial will study whether tranexamic acid can help treat hip fractures.

Eligible Conditions
  • Hip Fracture
  • Intertrochanteric Fractures

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~length of hospitalization (approximately 3 to 5 days)
This trial's timeline: 3 weeks for screening, Varies for treatment, and length of hospitalization (approximately 3 to 5 days) for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Number of Subjects Transfused at Least 1 Unit of Packed Red Blood Cells
Secondary outcome measures
(Myocardial Infarction) MI Diagnosed
All-cause Mortality
Calculated Blood Loss
+4 more

Trial Design

2Treatment groups
Active Control
Placebo Group
Group I: Tranexamic Acid Arm (TXA)Active Control1 Intervention
Subjects will be treated with early administration of TXA in the Emergency Department
Group II: Control ArmPlacebo Group1 Intervention
Subjects will be treated with a placebo in the Emergency Department

Find a Location

Who is running the clinical trial?

Mayo ClinicLead Sponsor
3,205 Previous Clinical Trials
3,766,736 Total Patients Enrolled
1 Trials studying Hip Fracture
138 Patients Enrolled for Hip Fracture
Brandon Yuan, MDPrincipal InvestigatorMayo Clinic
2 Previous Clinical Trials
70 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
Does Early Administration of Tranexamic Acid Reduce Blood Loss and Perioperative Transfusion Requirement
Brandon James Yuan 2018. "Does Early Administration of Tranexamic Acid Reduce Blood Loss and Perioperative Transfusion Requirement". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT03182751.
~18 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top